This post was originally published on this site
  • The market narrative on what a potential November blue wave could mean for stocks has flipped over the past two weeks, UBS said in a note on Monday.
  • The prevailing market narrative over the past few months that a blue wave election outcome would hurt stocks due to higher taxes is now dead, according to UBS.
  • Instead, expect stocks to move higher if there is a blue wave this November, and don’t be surprised for the potential of investors being disappointed if a blue wave doesn’t happen, UBS said.
  • Visit Business Insider’s homepage for more stories.

Throughout 2020, the consensus view has been that a Joe Biden victory, and a potential “blue wave” in November, would be bad for the stock market because of the potential for higher corporate taxes and more regulation.

But that market narrative has been flipped on its head in the past two weeks, UBS said in a note on Monday.

Now, investors expect a Biden victory and Democratic sweep of Congress this November to serve as a the catalyst for a reflation trade, in which cyclical and value stocks trade higher, and the US dollar weakens, further helping US stock prices.

The impetus for a change of heart among investors regarding a blue wave and its impact on stocks is three-fold, according to UBS:

1. “The inability to pass a major fiscal package prior to the election means that it’s increasingly likely to be the Democrats’ top priority after a Blue Wave outcome,” UBS said.

2. Higher taxes will be a 2022 problem for investors, not a 2021 problem, according to UBS.

Read more: GOLDMAN SACHS: Buy these 15 stocks set to deliver the strongest possible profit growth and subsequent returns through year-end

3. “Biden’s widening lead in the polls and prediction markets, and along with it the likelihood of a Blue Wave, is reducing election uncertainty,” UBS said, adding that a delayed or contested election is more unsettling to investors than a Democratic sweep of the White House and Congress.

This helps explain why stocks have been moving the way they have been over the past month. 

As the probabilities of a blue wave rose, and the potential for a pre-election fiscal stimulus deal fell, small- and large-cap value stocks surged, outperforming large-cap growth by a sizable margin. On top of that, the Treasury yield curve steepened 11 basis points, while commodities jumped and the US dollar fell. 

“In short, it’s the reflation trade,” UBS explained.  

Expect these trends to last over the next six to nine months, UBS said. But if too much optimism is priced in too soon, it could lead to the “perverse situation in which investors are disappointed if a Blue Wave doesn’t happen,” UBS said.

Read more: A $2 billion fund manager says market volatility is here to stay for the long-term. He breaks down his best recommendations for the new normal – including 4 of his favorite stocks.

Still, the reflation trade has more room to run, and not just because of the November election. 

“The most important catalyst for the [reflation] trade has nothing to do with the election, because it’s a vaccine,” UBS said, adding that early indications are “fairly promising” for the US to reach herd immunity levels by mid-2021. 

Expect the stock market to price in the economic benefits of herd immunity far sooner than when it actually happens, UBS concluded. 

Read more: The head of investment strategy at a $44 billion ETF shop explains why the pandemic-fueled boom of online retail is set to accelerate – and shares 5 stocks to watch other than Amazon ahead of its Prime Day